Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapy

References

• LiWZengSYuLSZhouQPharmacokinetic drug interaction profile of omeprazole with adverse consequences and clinical risk managementTher Clin Risk Manag2013925927123745048
   PubMed Web of Science ®Google Scholar
• ZhouYTYuLSZengSHuangYWXuHMZhouQPharmacokinetic drug–drug interactions between 1,4-dihydropyridine calcium channel blockers and statins: factors determining interaction strength and relevant clinical risk managementTher Clin Risk Manag201410172524379677
   PubMed Web of Science ®Google Scholar
• Joint Commission InternationalAccreditation Standards for Hospitals5th edOak Brook, IL, USAJoint Commission Resources2013
   Google Scholar
• WikipediaClopidogrel Available from: http://en.wikipedia.org/wiki/ClopidogrelAccessed January 2, 2014
   Google Scholar
• KounisNGGrapsasNPathways of platelet activation and unexplained clopidogel variability: causes of poor response to clopidogrelThromb Res201313231223714177
   PubMed Web of Science ®Google Scholar
• FerriNCorsiniABellostaSPharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic propertiesDrugs2013731681170924114622
   PubMed Web of Science ®Google Scholar
• EganGHughesCAAckmanMLDrug interactions between anti-platelet or novel oral anticoagulant medications and antiretroviral medicationsAnn Pharmacother20144873474024615627
   PubMed Web of Science ®Google Scholar
• ShahBSParmarSAMahajanSMehtaAAAn insight into the interaction between clopidogrel and proton pump inhibitorsCurr Drug Metab20121322523522300021
   PubMed Web of Science ®Google Scholar
• ScottSAOwusu ObengAHulotJSAntiplatelet drug interactions with proton pump inhibitorsExpert Opin Drug Metab Toxicol20141017518924205916
   PubMed Web of Science ®Google Scholar
• Siller-MatulaJMTrenkDKrähenbühlSMichelsonADDelle-KarthGClinical implications of drug–drug interactions with P2Y12 receptor inhibitorsJ Thromb Haemost20141221324406062
   PubMed Web of Science ®Google Scholar
• TabassomeSCelineVMurielleMKGenetic determinants of response to clopidogrel and cardiovascular eventsN Engl J Med200936036337519106083
   PubMed Web of Science ®Google Scholar
• KazuiMNishiyaYIshizukaTIdentification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metaboliteDrug Metab Dispos201038929919812348
   PubMed Web of Science ®Google Scholar
• FareedJJeskeWThethiIMetabolic differences of current thienopyridine antiplatelet agentsExpert Opin Drug Metab Toxicol2013930731723289968
   PubMed Web of Science ®Google Scholar
• FloydJSKasperaRMarcianteKDA screening study of drug–drug interactions in cerivastatin users: an adverse effect of clopidogrelClin Pharmacol Ther20129189690422419147
   PubMed Web of Science ®Google Scholar
• TornioAFilppulaAMKailariOGlucuronidation converts clopidogrel to a strong time-dependent inhibitor of CYP2C8: a phase II metabolite as a perpetrator of drug–drug interactionsClin Pharmacol Ther20149649850724971633
   PubMed Web of Science ®Google Scholar
• TamrazBFukushimaHWolfeAROATP1B1-related drug–drug and drug-gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysisPharmacogenet Genomics20132335536423652407
   PubMed Web of Science ®Google Scholar
• SchmidtMJohansenMBMaengMConcomitant use of clopidogrel and statins and risk of major adverse cardiovascular events following coronary stent implantationBr J Clin Pharmacol20127416117022243420
   PubMed Web of Science ®Google Scholar
• FaridNASmallDSPayneCDEffect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjectsPharmacotherapy2008281483149419025429
   PubMed Web of Science ®Google Scholar
• AyalasomayajulaSPVaidyanathanSKempCPrasadPBalchADoleWPEffect of clopidogrel on the steady-state pharmacokinetics of fluvastatinJ Clin Pharmacol20074761361917442686
   PubMed Web of Science ®Google Scholar
• PinheiroLFFrançaCNIzarMCPharmacokinetic interactions between clopidogrel and rosuvastatin: effects on vascular protection in subjects with coronary heart diseaseInt J Cardiol201215812512922569318
   PubMed Web of Science ®Google Scholar
• TengRMitchellPDButlerKAPharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteersEur J Clin Pharmacol20136947748722922682
   PubMed Web of Science ®Google Scholar
• ScheenAJDrug–drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinideClin Pharmacokinet2007469310817253883
   PubMed Web of Science ®Google Scholar
• YuLLuSLinYZengSCarboxyl-glucuronidation of mitiglinide by human UDP-glucuronosyltransferasesBiochem Pharmacol2007731842185117359941
   PubMed Web of Science ®Google Scholar
• ZhouDAnderssonTBGrimmSWIn vitro evaluation of potential drug–drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction, and differential kineticsDrug Metab Dispos20113970371021177984
   PubMed Web of Science ®Google Scholar
• LiYLiuCZhangYMiSWangNPharmacokinetics of ferulic acid and potential interactions with Honghua and clopidogrel in ratsJ Ethnopharmacol201113756256721704146
   PubMed Web of Science ®Google Scholar
• BaeSKCaoSSeoKACytochrome P450 2B6 catalyzes the formation of pharmacologically active sibutramine (N-{1-[1-(4-chloro-phenyl)cyclobutyl]-3-methylbutyl}-N,N-dimethylamine) metabolites in human liver microsomesDrug Metab Dispos2008361679168818474675
   PubMed Web of Science ®Google Scholar
• NishiyaYHagiharaKKuriharaAComparison of mechanism-based inhibition of human cytochrome P450 2C19 by ticlopidine, clopidogrel, and prasugrelXenobiotica20093983684319845434
   PubMed Web of Science ®Google Scholar
• BaeJWJangCGLeeSYEffects of clopidogrel on the pharmacokinetics of sibutramine and its active metabolitesJ Clin Pharmacol2011511704171121209232
   PubMed Web of Science ®Google Scholar
• PanWBaeSKShimEJEffects of clopidogrel and clarithromycin on the disposition of sibutramine and its active metabolites M1 and M2 in relation to CYP2B6*6 polymorphismXenobiotica20134321121822830954
   PubMed Web of Science ®Google Scholar
• PeetersPACrijnsHJTammingaWJJonkmanJHDickinsonJPNecciariJClopidogrel, a novel antiplatelet agent, and digoxin: absence of pharmacodynamic and pharmacokinetic interactionSemin Thromb Hemost199925Suppl 2515410440424
   PubMedGoogle Scholar
• TengRButlerKA pharmacokinetic interaction study of ticagrelor and digoxin in healthy volunteersEur J Clin Pharmacol2013691801180823748750
   PubMed Web of Science ®Google Scholar
• RxList®BRILINTA^® (ticagrelor) tabletsNew York, NY, USA Available from: http://www.rxlist.com/brilinta-drug/clinical-pharmacology.htmAccessed January 1, 2014
   Google Scholar
• AbdelhadyAMDestaZJiangFYeoCWShinJGOverholserBRPopulation pharmacogenetic-based pharmacokinetic modeling of efavirenz, 7-hydroxy- and 8-hydroxyefavirenzJ Clin Pharmacol201454879624142869
   PubMed Web of Science ®Google Scholar
• JiangFDestaZShonJHEffects of clopidogrel and itraconazole on the disposition of efavirenz and its hydroxyl metabolites: exploration of a novel CYP2B6 phenotyping indexBr J Clin Pharmacol20137524425322554354
   PubMed Web of Science ®Google Scholar
• XuCOgburnETGuoYDestaZEffects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivoDrug Metab Dispos20124071772522232427
   PubMed Web of Science ®Google Scholar
• ChenBLChenYTuJHClopidogrel inhibits CYP2C19-dependent hydroxylation of omeprazole related to CYP2C19 genetic polymorphismsJ Clin Pharmacol20094957458119398604
   PubMed Web of Science ®Google Scholar
• AngiolilloDJGibsonCMChengSDifferential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studiesClin Pharmacol Ther201189657420844485
   PubMed Web of Science ®Google Scholar
• FrelingerAL3rdLeeRDMulfordDJA randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lanso-prazole, esomeprazole, and omeprazole on the steady-state pharma-cokinetics and pharmacodynamics of clopidogrel in healthy volunteersJ Am Coll Cardiol2012591304131122464259
   PubMed Web of Science ®Google Scholar
• JohnsonDAChiltonRLikerHRProton-pump inhibitors in patients requiring antiplatelet therapy: new FDA labelingPostgrad Med201412623924524918808
   PubMed Web of Science ®Google Scholar
• HarmszeAMvan WerkumJWTaubertDHackengCMDeneerVHEsomeprazole but not pantoprazole is associated with lower plasma concentrations of clopidogrel’s active metaboliteAnn Pharmacother20114554254321487078
   PubMed Web of Science ®Google Scholar
• Funck-BrentanoCSzymezakJSteichenOEffects of rabeprazole on the antiplatelet effects and pharmacokinetics of clopidogrel in healthy volunteersArch Cardiovasc Dis201310666167124246616
   PubMed Web of Science ®Google Scholar
• WuJJiaLTShaoLMDrug–drug interaction of rabeprazole and clopidogrel in healthy Chinese volunteersEur J Clin Pharmacol20136917918722706585
   PubMed Web of Science ®Google Scholar
• FerreiroJLUenoMCapodannoDPharmacodynamic effects of concomitant versus staggered clopidogrel and omeprazole intake: results of a prospective randomized crossover studyCirc Cardiovasc Interv2010343644120858862
   PubMed Web of Science ®Google Scholar
• MoceriPDoyenDCerboniPFerrariEDoubling the dose of clopidogrel restores the loss of antiplatelet effect induced by esomeprazoleThromb Res201112845846221777954
   PubMed Web of Science ®Google Scholar
• ColletJPHulotJSAbtanJPrasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: results of the randomized DOSAPI studyEur J Clin Pharmacol2014701049105725012577
   PubMed Web of Science ®Google Scholar
• SmallDSFaridNALiYGEffect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrelCurr Med Res Opin2008242251225718786302
   PubMed Web of Science ®Google Scholar
• OhbuchiMNoguchiKKawamuraAUsuiTDifferent effects of proton pump inhibitors and famotidine on the clopidogrel metabolic activation by recombinant CYP2B6, CYP2C19 and CYP3A4Xenobiotica20124263364022313038
   PubMed Web of Science ®Google Scholar
• SmallDSFaridNAPayneCDEffects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrelJ Clin Pharmacol20084847548418303127
   PubMed Web of Science ®Google Scholar
• HoblELStimpflTEbnerJMorphine decreases clopidogrel concentrations and effects: a randomized, double-blind, placebo-controlled trialJ Am Coll Cardiol20146363063524315907
   PubMed Web of Science ®Google Scholar
• ParodiGValentiRBellandiBComparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI studyJ Am Coll Cardiol2013611601160623500251
   PubMed Web of Science ®Google Scholar
• ChenXJinJChenYEffect of scutellarin on the metabolism and pharmacokinetics of clopidogrel in ratsBiopharm Drug Dispos201536646825256597
   PubMed Web of Science ®Google Scholar
• DelavenneXMagninMBassetTInvestigation of drug–drug interactions between clopidogrel and fluoxetineFundam Clin Pharmacol20132768368923413998
   PubMed Web of Science ®Google Scholar
• TengRKujacicMHsiaJEvaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjectsClin Ther2014361217122525069798
   PubMed Web of Science ®Google Scholar
• OganesianAShillingADYoung-SciameRDesvenlafaxine and venlafaxine exert minimal in vitro inhibition of human cytochrome P450 and P-glycoprotein activitiesPsychopharmacol Bull200942476319629022
   PubMed Web of Science ®Google Scholar
• FaridNAPayneCDSmallDSCytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differentlyClin Pharmacol Ther20078173574117361128
   PubMed Web of Science ®Google Scholar
• SuhJWKooBKZhangSYIncreased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrelCMAJ20061741715172216754899
   PubMed Web of Science ®Google Scholar
• HarmszeAMRobijnsKvan WerkumJWThe use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor responseThromb Haemost201010392092520352154
   PubMed Web of Science ®Google Scholar
• SeoKDKimYDYoonYWKimJYLeeKYAntiplatelet effect of clopidogrel can be reduced by calcium channel blockersYonsei Med J20145568368824719135
   PubMed Web of Science ®Google Scholar
• ParkJJParkKWKangJCYP3A4 genetic status may be associated with increased vulnerability to the inhibitory effect of calcium-channel blockers on clopidogrelCirc J2013771289129623400261
   PubMed Web of Science ®Google Scholar
• HarmszeAMVan WerkumJWMoralFSulfonylureas and on-clopidogrel platelet reactivity in type 2 diabetes mellitus patientsPlatelets2011229810221142408
   PubMed Web of Science ®Google Scholar
• HarmszeAMvan WerkumJWBoumanHJBesides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantationPharmacogenet Genomics201020182519934793
   PubMed Web of Science ®Google Scholar
• TengRMitchellPButlerKEvaluation of the pharmacokinetic interaction between ticagrelor and tolbutamide, a cytochrome P450 2C9 substrate, in healthy volunteersInt J Clin Pharmacol Ther20135130531223380426
   PubMed Web of Science ®Google Scholar
• MetzgerNLMomaryKMA patient with HIV and tuberculosis with diminished clopidogrel responseInt J STD AIDS20132553253424352136
   PubMed Web of Science ®Google Scholar
• AncrenazVDéglonJSamerCPharmacokinetic interaction between prasugrel and ritonavir in healthy volunteersBasic Clin Pharmacol Toxicol201311213213722900583
   PubMed Web of Science ®Google Scholar
• DaaliYAncrenazVBosilkovskaMDayerPDesmeulesJRitonavir inhibits the two main prasugrel bioactivation pathways in vitro: a potential drug–drug interaction in HIV patientsMetabolism2011601584158921550074
   PubMed Web of Science ®Google Scholar
• JungKHChuKLeeSTProlonged use of aspirin alters human and rat intestinal cells and thereby limits the absorption of clopidogrelClin Pharmacol Ther20119061261921900887
   PubMed Web of Science ®Google Scholar
• OhJShinDLimKSAspirin decreases systemic exposure to clopidogrel through modulation of P-glycoprotein but does not alter its antithrombotic activityClin Pharmacol Ther20149560861624566733
   PubMed Web of Science ®Google Scholar
• LiangYHirshJWeitzJIActive metabolite concentration of clopidogrel in patients taking different doses of aspirin: results of the Interaction TrialJ Thromb Haemost12302014 [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• TaubertDvon BeckerathNGrimbergGImpact of P-glycoprotein on clopidogrel absorptionClin Pharmacol Ther20068048650117112805
   PubMed Web of Science ®Google Scholar
• ChenXPTanZRHuangSLHuangZOu-YangDSZhouHHIsozyme-specific induction of low-dose aspirin on cytochrome P450 in healthy subjectsClin Pharmacol Ther20037326427112621391
   PubMed Web of Science ®Google Scholar
• BoumanHJ1SchömigEvan WerkumJWParaoxonase-1 is a major determinant of clopidogrel efficacyNat Med20111711011621170047
   PubMed Web of Science ®Google Scholar
• JaichanderPSelvarajanKGarelnabiMParthasarathySInduction of paraoxonase 1 and apolipoprotein A-I gene expression by aspirinJ Lipid Res2008492142214818519978
   PubMed Web of Science ®Google Scholar
• LiuACZhaoLXLouHXCurcumin alters the pharmacokinetics of warfarin and clopidogrel in Wistar rats but has no effect on anticoagulation or antiplatelet aggregationPlanta Med20137997197723807811
   PubMed Web of Science ®Google Scholar
• HeXMoLLiZYTanZRChenYOuyangDSEffects of curcumin on the pharmacokinetics of talinolol in human with ABCB1 polymorphismXenobiotica2012421248125422725663
   PubMed Web of Science ®Google Scholar
• TranaCTothGWijnsWBarbatoEClopidogrel undergoing percutaneous coronary intervention: a single-center randomized open-label trial (St John’s Trial)J Cardiovasc Transl Res2013641141423463297
   PubMed Web of Science ®Google Scholar
• LauWCWelchTDShieldsTRubenfireMTantryUSGurbelPAThe effect of St John’s wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of CYP3A4 metabolic activityJ Cardiovasc Pharmacol201157869320980920
   PubMed Web of Science ®Google Scholar
• LeeJHShinYJKimHJOhJHJangYPLeeYJDanshen extract does not alter pharmacokinetics of docetaxel and clopidogrel, reflecting its negligible potential in P-glycoprotein- and cytochrome P4503A-mediated herb-drug interactionsInt J Pharm2011410687421421030
   PubMed Web of Science ®Google Scholar
• LeeJHShinYJOhJHLeeYJPharmacokinetic interactions of clopidogrel with quercetin, telmisartan, and cyclosporine A in rats and dogsArch Pharm Res2012351831183723139136
   PubMed Web of Science ®Google Scholar
• TengRKujacicMHsiaJPharmacokinetic interaction study of ticagrelor and cyclosporine in healthy volunteersClin Drug Investig201434529536
   PubMed Web of Science ®Google Scholar
• JudgeHMPatilSBBucklandRJJakubowskiJAStoreyRFPotentiation of clopidogrel active metabolite formation by rifampicin leads to greater P2Y12 receptor blockade and inhibition of platelet aggregation after clopidogrelJ Thromb Haemost201081820182720492465
   PubMed Web of Science ®Google Scholar
• TengRMitchellPButlerKEffect of rifampicin on the pharmacokinetics and pharmacodynamics of ticagrelor in healthy subjectsEur J Clin Pharmacol20136987788323093043
   PubMed Web of Science ®Google Scholar
• FaridNAJakubowskiJAPayneCDEffect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjectsCurr Med Res Opin2009251821182919530977
   PubMed Web of Science ®Google Scholar
• KristensenKEZhuHJWangXClopidogrel bioactivation and risk of bleeding in patients cotreated with angiotensin-converting enzyme inhibitors after myocardial infarction: a proof-of-concept studyClin Pharmacol Ther20149671372225222620
   PubMed Web of Science ®Google Scholar
• YousefAMArafatTBulatovaNRSmoking behaviour modulates pharmacokinetics of orally administered clopidogrelJ Clin Pharm Ther20083343944918613862
   PubMed Web of Science ®Google Scholar
• HochholzerWTrenkDMegaJLImpact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapyAm Heart J201116251852621884870
   PubMed Web of Science ®Google Scholar
• ParkKWParkJJJeonKHEnhanced clopidogrel responsiveness in smokers: smokers’ paradox is dependent on cytochrome P450 CYP1A2 statusArterioscler Thromb Vasc Biol20113166567121148426
   PubMed Web of Science ®Google Scholar
• GurbelPABlidenKPLoganDKThe influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX studyJ Am Coll Cardiol20136250551223602770
   PubMed Web of Science ®Google Scholar
• CaplainHThebaultJJNecciariJClopidogrel does not affect the pharmacokinetics of theophyllineSemin Thromb Hemost199925Suppl 2656810440427
   PubMedGoogle Scholar
• NirogiRVKandikereVNMudigondaKEffect of food on bioavailability of a single oral dose of clopidogrel in healthy male subjectsArzneimittelforschung20065673573917220050
   PubMed Web of Science ®Google Scholar
• HurbinFBoulencXDaskalakisNClopidogrel pharmacodynamics and pharmacokinetics in the fed and fasted state: a randomized crossover study of healthy menJ Clin Pharmacol2012521506151522128201
   PubMed Web of Science ®Google Scholar
• TengRMitchellPDButlerKLack of significant food effect on the pharmacokinetics of ticagrelor in healthy volunteersJ Clin Pharm Ther20123746446821967645
   PubMed Web of Science ®Google Scholar
• SmallDSFaridNAPayneCDEffect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrelClin Pharmacokinet20104977779821053990
   PubMed Web of Science ®Google Scholar
• HolmbergMTTornioANeuvonenMNeuvonenPJBackmanJTNiemiMGrapefruit juice inhibits the metabolic activation of clopidogrelClin Pharmacol Ther20149530731324067745
   PubMed Web of Science ®Google Scholar
• HolmbergMTTornioAJoutsi-KorhonenLGrapefruit juice markedly increases the plasma concentrations and antiplatelet effects of ticagrelor in healthy subjectsBr J Clin Pharmacol2013751488149623126367
   PubMed Web of Science ®Google Scholar
• CampbellKLCohnJRFischmanDLManagement of clopidogrel hypersensitivity without drug interruptionAm J Cardiol201110781281621247516
   PubMed Web of Science ®Google Scholar
• KarabayCYCanMMTanboğaIHAhmetGBitigenASerebruanyVRecurrent acute stent thrombosis due to allergic reaction secondary to clopidogrel therapyAm J Ther201118e119e12220683245
   PubMed Web of Science ®Google Scholar
• KounisNGSoufrasGDCoronary stent thrombosis: beware of an allergic reaction and of Kounis syndromeIndian Heart J20146615315524814107
   PubMedGoogle Scholar